DE60117096T2 - Dihydroindol- und tetrahydrochinolinderivate - Google Patents

Dihydroindol- und tetrahydrochinolinderivate Download PDF

Info

Publication number
DE60117096T2
DE60117096T2 DE60117096T DE60117096T DE60117096T2 DE 60117096 T2 DE60117096 T2 DE 60117096T2 DE 60117096 T DE60117096 T DE 60117096T DE 60117096 T DE60117096 T DE 60117096T DE 60117096 T2 DE60117096 T2 DE 60117096T2
Authority
DE
Germany
Prior art keywords
dihydro
methylamino
allyl
indol
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60117096T
Other languages
German (de)
English (en)
Other versions
DE60117096D1 (de
Inventor
Johannes Aebi
Jean Ackermann
Alexander San Diego CHUCHOLOWSKI
Henrietta Dehmlow
Olivier Morand
Sabine Wallbaum
Thomas Weller
Narendra Panday
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60117096D1 publication Critical patent/DE60117096D1/de
Publication of DE60117096T2 publication Critical patent/DE60117096T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
DE60117096T 2000-12-21 2001-12-12 Dihydroindol- und tetrahydrochinolinderivate Expired - Lifetime DE60117096T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00128063 2000-12-21
EP00128063 2000-12-21
PCT/EP2001/014620 WO2002050041A1 (en) 2000-12-21 2001-12-12 Dihydroindole and tetrahydroquinoline derivatives

Publications (2)

Publication Number Publication Date
DE60117096D1 DE60117096D1 (de) 2006-04-20
DE60117096T2 true DE60117096T2 (de) 2006-11-23

Family

ID=8170751

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117096T Expired - Lifetime DE60117096T2 (de) 2000-12-21 2001-12-12 Dihydroindol- und tetrahydrochinolinderivate

Country Status (15)

Country Link
US (2) US6706751B2 (enExample)
EP (1) EP1358162B1 (enExample)
JP (1) JP4068459B2 (enExample)
KR (1) KR100530408B1 (enExample)
CN (1) CN1208322C (enExample)
AR (1) AR035408A1 (enExample)
AT (1) ATE317386T1 (enExample)
AU (2) AU1917602A (enExample)
BR (1) BR0116263A (enExample)
CA (1) CA2431100C (enExample)
DE (1) DE60117096T2 (enExample)
ES (1) ES2257381T3 (enExample)
MX (1) MXPA03005395A (enExample)
WO (1) WO2002050041A1 (enExample)
ZA (1) ZA200304646B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
CA2495943C (en) * 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2005014755A1 (ja) * 2003-08-08 2005-02-17 Ube Industries, Ltd. アルキニル基置換縮合ヘテロ環化合物及びその製法並びにそれを使用する有機エレクトロルミネッセンス素子
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
WO2008124300A1 (en) * 2007-04-10 2008-10-16 National Health Research Institutes Hepatitis c virus inhibitors
TW200848016A (en) * 2007-06-08 2008-12-16 Nat Health Research Institutes Thiourea compound and composition of treating hepatitis C virus infection
TWI361808B (en) * 2008-01-08 2012-04-11 Nat Health Research Institutes Imidazolidinone and imidazolidinethione derivatives
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997542A (en) * 1975-06-23 1976-12-14 Sterling Drug Inc. 1-(Halogenated-acetyl)-1,2,3,4-tetrahydro-6-quinolinols and esters thereof
NZ227042A (en) 1987-11-27 1991-05-28 Banyu Pharma Co Ltd Substituted alkylamine derivatives and pharmaceutical compositions
US5288749A (en) 1991-12-20 1994-02-22 Abbott Laboratories Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
TW438774B (en) 1993-07-14 2001-06-07 Hoffmann La Roche Pharmaceutical composition for lowering cholesterol containing phenalkylamines and certain novel phenalkylamines
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
DE19727117A1 (de) 1997-06-26 1999-01-07 Boehringer Ingelheim Pharma Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS

Also Published As

Publication number Publication date
WO2002050041A1 (en) 2002-06-27
AU1917602A (en) 2002-07-01
CN1481366A (zh) 2004-03-10
US7102007B2 (en) 2006-09-05
ES2257381T3 (es) 2006-08-01
US20030004156A1 (en) 2003-01-02
MXPA03005395A (es) 2003-09-25
KR100530408B1 (ko) 2005-11-22
CN1208322C (zh) 2005-06-29
ATE317386T1 (de) 2006-02-15
US6706751B2 (en) 2004-03-16
EP1358162B1 (en) 2006-02-08
JP2004519441A (ja) 2004-07-02
KR20030063453A (ko) 2003-07-28
AR035408A1 (es) 2004-05-26
DE60117096D1 (de) 2006-04-20
ZA200304646B (en) 2004-09-13
CA2431100C (en) 2009-03-24
JP4068459B2 (ja) 2008-03-26
BR0116263A (pt) 2003-12-30
CA2431100A1 (en) 2002-06-27
EP1358162A1 (en) 2003-11-05
US20050020624A1 (en) 2005-01-27
AU2002219176B2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
EP0515240B1 (fr) Composés N-(aminoalkyl)pipéridine et leurs énantiomères comme antagonistes des récepteurs des neurokinines, procédés pour leur préparation et compositions pharmaceutiques les contenant
US5569674A (en) Heteroacetic acid derivatives
US7244758B2 (en) N-type calcium channel blockers
DE60035039T2 (de) Renin-inhibitoren
JP2000516955A (ja) 置換環状アミンメタロプロテアーゼ阻害剤
EP0778271A2 (de) Aminoalkyl-substituierte benzo-heterocyclische Verbindungen
EP0474561A1 (fr) Arylalkylamines, procédé pour leur préparation et compositions pharmaceutiques les contenant
EP0147768A2 (de) Glycerinderivate
US4510156A (en) Bisindolyl alkylene ureas lipid absorption-inhibiting agents and their use thereas
TW200800167A (en) Organic compounds
EP1358162B1 (en) Dihydroindole and tetrahydroquinoline derivatives
DE60216319T2 (de) Heteroaryl-substituierte aminocyclohexan-derivate
US20120142735A1 (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]- 1h-indol-3-yl]-methanones
DE60108164T2 (de) Cholesterin senkende Benzo[b]thiophene und Benzo[d]isothiazole
DE60132468T2 (de) Piperidin-derivate zur verwendung als 2,3-oxidosqualen-lanosterol zyklase inhibitoren
DE60118970T2 (de) Indol- und dihydroindolderivate
DE60216967T2 (de) Substituierte cyclohexanderivate
JPH06502415A (ja) オキシスルホニルカルバメート
CN114478359A (zh) 氨基甲酸酯类trpv1拮抗/faah抑制双靶点药物及其制备方法和应用
SG181501A1 (en) Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
EP0663395A1 (de) 3-(Phenylalkylaminoalkyloxy)-5-phenylpyrazol-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihrer Verwendung als herzfrequenzsenkendes Mittel
US6187770B1 (en) N-substituted azaheterocyclic compounds
CS215072B2 (en) Method of making the new decahydrochynoline derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition